Trial delays, Q1 profit slide pushes Neovasc shares down

Delays in Neovasc’s early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits push its stock price down.

Delays in Neovasc's (NSDQ:NVCN) early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits combined to push its stock price down this week.

Neovasc Inc.

News Well, Clinical Trials, MassDevice.com Earnings Roundup, 2015, Q1, Replacement Heart Valves

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1EL6vrl